Mouse Anti-CIP2A Recombinant Antibody (1-C4) (CBMAB-K0303-LY)

Kauko, O., Imanishi, S. Y., Kulesskiy, E., Yetukuri, L., Laajala, T. D., Sharma, M., ... & Westermarck, J. (2020). Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1. Journal of Biological Chemistry, 295(13), 4194-4211.

Liu, C. Y., Huang, T. T., Chen, Y. T., Chen, J. L., Chu, P. Y., Huang, C. T., ... & Tseng, L. M. (2019). Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression. EBioMedicine, 40, 263-275.

Shentu, Y. P., Huo, Y., Feng, X. L., Gilbert, J., Zhang, Q., Liuyang, Z. Y., ... & Liu, R. (2018). CIP2A causes Tau/APP phosphorylation, synaptopathy, and memory deficits in Alzheimer’s disease. Cell reports, 24(3), 713-723.

Zhang, Y., Huang, P., Liu, X., Xiang, Y., Zhang, T., Wu, Y., ... & Liu, Y. (2018). Polyphyllin I inhibits growth and invasion of cisplatin-resistant gastric cancer cells by partially inhibiting CIP2A/PP2A/Akt signaling axis. Journal of pharmacological sciences, 137(3), 305-312.

Lucas, C. M., Scott, L. J., Carmell, N., Holcroft, A. K., Hills, R. K., Burnett, A. K., & Clark, R. E. (2018). CIP2A-and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML. Blood advances, 2(9), 964.

Yang, X., Qu, K., Tao, J., Yin, G., Han, S., Liu, Q., & Sun, H. (2018). Inhibition of CIP2A attenuates tumor progression by inducing cell cycle arrest and promoting cellular senescence in hepatocellular carcinoma. Biochemical and biophysical research communications, 495(2), 1807-1814.

Zhao, M., Howard, E. W., Parris, A. B., Guo, Z., Zhao, Q., Ma, Z., ... & Yang, X. (2017). Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells. Oncotarget, 8(35), 58847.

Soofiyani, S. R., Hejazi, M. S., & Baradaran, B. (2017). The role of CIP2A in cancer: a review and update. Biomedicine & Pharmacotherapy, 96, 626-633.

Bartalucci, N., Calabresi, L., Balliu, M., Martinelli, S., Rossi, M. C., Villeval, J. L., ... & Vannucchi, A. M. (2017). Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/CIP2A axis. Oncotarget, 8(57), 96710.

Huang, Q., Qin, S., Yuan, X., Zhang, L., Ji, J., Liu, X., ... & Liu, Y. (2017). Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A. Oncology reports, 38(1), 598-606.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Related Products

Rabbit Anti-CIP2A Recombinant Antibody (D1M3H)

Mouse Anti-CIP2A Recombinant Antibody (8B68)

Mouse Anti-CIP2A Recombinant Antibody (9E6)

Mouse Anti-CIP2A Recombinant Antibody (CBFYC-1875)

Mouse Anti-CIP2A Recombinant Antibody (1C11)

Mouse Anti-CIP2A Recombinant Antibody (2A1-9A4)

Mouse Anti-CIP2A Recombinant Antibody (4F5)

Mouse Anti-CIP2A Recombinant Antibody (9-G10)

Mouse Anti-CIP2A Recombinant Antibody (CBXC-2761)

Mouse Anti-CIP2A Recombinant Antibody (2G10)

Isotype control